form_8-k.htm
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington,
DC 20549
_______________
Form 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of
report (date of earliest event reported):
November
6, 2008
SCOLR
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-31982
|
|
91-1689591
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File No.)
|
|
(I.R.S.
Employer Identification No.)
|
19204
North Creek Parkway, Suite 100
Bothell,
WA 98011
(Address
of principal executive offices)
(425) 368-1050
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item 2.02
Results of Operations and Financial Condition.
On
November 7, 2008, SCOLR Pharma, Inc. announced its financial results for the
third quarter of 2008. A copy of the press release containing the announcement
is attached to this current report as Exhibit 99.1.
Item
8.01 Other Events.
On
November 6, 2008, SCOLR Pharma, Inc. announced top-line
results from its pivotal clinical trial evaluating efficacy of extended-release
ibuprofen. A copy of
the press release is attached to this current report as Exhibit
99.2.
The
information contained herein, including the exhibits attached and incorporated
herein by reference, is being furnished and shall not be deemed "filed" for
purposes of Section 18 of the Securities and Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information contained
herein and in the accompanying exhibits shall not be incorporated by reference
into any filing with the U.S. Securities and Exchange Commission made by the
Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filings.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
|
Exhibit No.
|
Description
|
|
99.1
|
SCOLR
Pharma, Inc. press release, dated November 7, 2008.
|
| 99.2 |
SCOLR
Pharma, Inc. press release, dated November 6,
2008. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
SCOLR
PHARMA, INC.
|
|
Dated: November
7, 2008
|
By:
|
/s/
Daniel O. Wilds
|
|
|
|
Daniel
O. Wilds
President
and Chief Executive Officer
|
3